about
Drug delivery of the future: Chasing the invisible gorillaCurrent Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided ApproachesNanotechnology in the war against cancer: new arms against an old enemy - a clinical view.Extracellularly activatable nanocarriers for drug delivery to tumors.Nanoparticle-based drug delivery systems: What can they really do in vivo?Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo.Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicineEnzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.Controlled Drug Delivery: Historical perspective for the next generation.Albumin and Hyaluronic Acid-Coated Superparamagnetic Iron Oxide Nanoparticles Loaded with Paclitaxel for Biomedical Applications.Enhanced transfection efficiency and targeted delivery of self-assembling h-R3-dendriplexes in EGFR-overexpressing tumor cells.Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.Drug Delivery Research: The Invention Cycle.Gold nanoparticles and their alternatives for radiation therapy enhancement.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.An overview of nanosomes delivery mechanisms: trafficking, orders, barriers and cellular effects.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors.Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse.Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges.Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors.From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.Nanomedicine Strategies to Target Tumor-Associated Macrophages.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.A cooperative polymeric platform for tumor-targeted drug delivery.A Biomimetic Microfluidic Tumor Microenvironment Platform Mimicking the EPR Effect for Rapid Screening of Drug Delivery Systems.Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency.Polymer-iron oxide composite nanoparticles for EPR-independent drug delivery.Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
P2860
Q24289432-65C5BCB9-0664-4C75-B180-A92CB0A3C601Q27002209-22B9B0CB-B92E-4451-8B26-CB4F5EE4A85DQ30354223-C311A961-F064-4AFD-A33C-B3F996C4B103Q30376531-8787CB2D-E676-4ABE-9456-8BB11A4C123DQ30401826-EA227C2D-ABBB-4F90-B3D3-42093C8E1E04Q33772186-82D9E499-908A-4BEB-9E71-17FE0E817400Q33918405-CDD92C91-890F-4860-A0BF-F0A3E1081FCCQ34698624-C564691C-6876-419D-AB61-677251D667F4Q36024654-19440524-A23E-4C25-805B-A8F435282ED1Q36307613-D6A33036-9292-4837-B925-B934A51D70C7Q36412229-4C9EED1E-FEA8-477A-B45B-120514AAB348Q36413402-58D75A33-733B-4269-94EB-28B736732283Q36414417-CB1A7EDA-1A97-4A1B-A3E2-5E7798318E3EQ36946804-D954602B-416F-49AB-B978-2196C1147A91Q37362790-EB71C9B6-A8D3-4BBA-931C-483AA93A5F05Q37641818-D2263353-C434-4482-A5F8-0DB814465748Q37659183-D4F31233-464A-4FF0-B30C-8D6B9F7C1E90Q38263536-B5461508-952C-418A-B133-D7A40FE163ABQ38555082-EA58AC29-DE87-4193-B9A5-6F77D08D9FB6Q38557213-B350C7F1-A92B-41AC-BE5E-CBD46A72D07EQ38577297-45805049-89A5-448C-B22E-0C83693B4919Q38663657-E8E717F7-1795-4D65-98A0-144E83F37350Q38676164-AC7CFC99-4AD2-468C-845F-45B4525DF8E9Q38703125-C4CCD840-258D-4370-8F90-E51ADA599BFBQ38733888-052BD044-1F36-4C77-A1DF-F6A0B2C4B9D9Q38797396-B8158A3F-AEE0-419A-B289-C3C15E81F7F7Q38808823-BCA28391-4263-4550-87C5-1001244D59E2Q38881452-B3E821A9-B487-4280-8A19-66980FA311F3Q38899902-425074E6-6B78-40E1-BA46-EDCEFF28014DQ38943053-F0568A11-D18E-4671-ADDD-773F96F57734Q38978632-9D08AA9D-0AF8-4BC0-ABA2-1732E7927CDFQ38981743-28835F58-0D26-413A-AF06-5C9AE8D18A60Q39060269-B3081B8A-7EF1-4EFB-A6F5-BAE1697AD61DQ39283111-46EF7D0C-D347-4974-80E0-584EFFD8FB46Q40468319-47A983DC-9C34-44AD-8EC4-91B004F7E8CCQ41144001-DA897273-E5F8-4154-9C2D-1F84CDDB7FD0Q41518143-7F4653F5-DFED-4D98-9306-68ED3ED92379Q42082847-CD24ADC2-6853-45B1-B441-86347B25B986Q42534599-B5CFB53D-09DB-444C-89AA-62758599BDCEQ45324119-A74CAD85-C4FD-48AE-8247-CCC8F85C9DD6
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
EPR: Evidence and fallacy.
@ast
EPR: Evidence and fallacy.
@en
EPR: Evidence and fallacy.
@nl
type
label
EPR: Evidence and fallacy.
@ast
EPR: Evidence and fallacy.
@en
EPR: Evidence and fallacy.
@nl
prefLabel
EPR: Evidence and fallacy.
@ast
EPR: Evidence and fallacy.
@en
EPR: Evidence and fallacy.
@nl
P1476
EPR: Evidence and fallacy.
@en
P2093
Joseph W Nichols
You Han Bae
P304
P356
10.1016/J.JCONREL.2014.03.057
P407
P577
2014-04-30T00:00:00Z